US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...
Novo Nordisk and Eli Lilly's motion to dismiss took aim at most of the counts asserted in the plaintiffs’ master long-form ...
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback